IL10 and campylobacteriosis: Our pre-clinical placebo-controlled intervention study provides evidence that prophylactic oral application of AC mitigates acute campylobacteriosis in hma IL-10−/− mice and could open novel avenues for both, the prevention and treatment of human C. jejuni infection due to its multi-facetted modes of action including binding and inactivation of viable pathogens, of endotoxins, and of pro-inflammatory mediators.